# Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis

> **NCT03025269** · — · COMPLETED · sponsor: **University at Buffalo** · enrollment: 30 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT03025269
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2022-01-08
- **Final completion:** 2022-01-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025269, "Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03025269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*